<DOC>
	<DOCNO>NCT02641353</DOCNO>
	<brief_summary>The purpose study assess much apremilast find blood unchanged administer oral suspension compare administered tablet formulation . The effect food apremilast oral suspension also evaluate . In addition , information safety tolerability apremilast obtain . CC-10004 ( also know apremilast Otezla® ) approve Food Drug Administration ( FDA ) treatment active psoriatic arthritis ( PsA ) moderate severe plaque psoriasis adult . The liquid formulation apremilast investigational drug develop Celgene Corporation treat plaque psoriasis child . An investigational drug approve U.S. Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>Study Evaluate Bioavailability Apremilast Oral Suspension Relative Tablet Study Assess Effect Food Pharmacokinetic ( PK ) Oral Suspension</brief_title>
	<detailed_description>This phase 1 , open-label , randomize , three-period , six-sequence crossover study healthy subject . The study consist screen phase , baseline phase , three study period , follow-up phone call . Each study period four day duration ( Day 1 Day 4 ) dosing follow five-day washout dos . Within 21 day ( Day -21 ) less two day ( Day -2 ) prior start first study period , subject undergo routine screening procedure include 12-lead electrocardiogram ( ECG ) , vital sign , clinical laboratory safety test , serology screen , pregnancy FSH testing , drug/alcohol screen . Eligible subject admit study center Day -1 study Period 1 baseline measurement . During study period , subject receive single 30 mg oral dose apremilast Day 1 accord assign treatment sequence . Subjects domicile study center Day 1 study Period 1 Day 4 study Period 3 , include 5 day washout dos . All subject discharge study center Day 4 study Period 3 follow completion require study procedure . A follow-up phone call occur approximately four day ( ±2 day ) discharge study center . The study conduct compliance International Conference Harmonisation ( ICH ) Good Clinical Practices ( GCPs ) .</detailed_description>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must satisfy ALL follow criterion eligible enrollment study : 1 . Must understand voluntarily sign write Informed Consent ( ICF ) prior studyrelated procedure perform . 2 . Must able communicate investigator , understand comply requirement study , agree adhere restriction examination schedule . 3 . Male female subject race 18 55 year age ( inclusive ) , good health determine Investigator time sign informed consent document . 4 . Have Boday Mass Index ( BMI ) 18 33 kg/m2 ( inclusive ) . 5 . No clinically significant laboratory test result determine investigator . 6 . At screen visit , must afebrile , supine systolic BP : 90 140 mmHg , supine diastolic BP : 50 90 mmHg , pulse rate : 40 110 bpm . Eligibility criteria vital sign perform checkin and/or predose Day 1 discretion Investigator . 7 . Must normal clinically acceptable 12lead Electrocardiogram ( ECG ) . Subjects must QTcF value ≤ 450 msec . 8 . Contraception Requirements : Must comply follow acceptable form contraception . All FCBP must use one approve contraceptive option describe take apremilast least 28 day administration last dose apremilast . At time study entry , time study FCBP 's contraceptive measure ability become pregnant change , Investigator educate subject regard contraception option correct consistent use effective contraceptive method order successfully prevent pregnancy All FCBP must negative pregnancy test Visits 1 2 . All FCBP subject engage activity conception possible must use one approve contraceptive option describe : Option 1 : Any one follow highly effective method : hormonal contraception ( oral , injection , implant , transdermal patch , vaginal ring ) ; intrauterine device ( IUD ) ; tubal ligation ; partner 's vasectomy ; OR Option 2 : Male female condom ( latex condom nonlatex condom NOT make natural [ animal ] membrane [ example , polyurethane ] ) ; PLUS one follow additional barrier method : ( ) diaphragm spermicide ; ( b ) cervical cap spermicide ; ( c ) contraceptive sponge spermicide . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception ( latex nonlatex condom NOT make natural [ animal ] membrane [ example , polyurethane ] ) IP least 28 day last dose IP . 9 . Must agree refrain donate sperm , blood plasma ( study ) participate study least 28 day last dose investigational product . 10 . Subject willing able adhere study visit schedule protocol requirement The presence ANY follow exclude healthy subject enrollment study : 1 . History clinically significant relevant neurological , psychiatric , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , allergic disease , drug allergy , major disorder . 2 . Any condition place subject unacceptable risk participate study , confound ability interpret data study . 3 . Use prescribed systemic topical medication within 30 day first dose administration . 4 . Use nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine ) within 14 day first dose administration , Any surgical medical condition possibly affect drug absorption , distribution , metabolism excretion , eg , bariatric procedure , colon resection , irritable bowel syndrome , Crohn 's disease , etc . Subjects cholecystectomy appendectomy may include . 5 . Exposure investigational drug ( new chemical entity ) within 30 day prior first dose administration 5 halflives investigational drug , know ( whichever longer ) . 6 . Donated blood plasma within 8 week first dose administration blood bank blood donation center . 7 . History drug abuse ( define current version Diagnostic Statistical Manual [ DSM ] ) within 2 year dose , positive drug screen reflect consumption illicit drug . 8 . History alcohol abuse ( define current version DSM ) within 2 year dose , positive alcohol screen . 9 . Known hepatitis , know carrier HBsAg , HCV Ab , positive result test HBsAg , HCV Ab , HIV antibodies Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Apremilast</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Food effect</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>